title: Beneficial effects of non-matched allogeneic cord blood mononuclear cells upon patients with idiopathic osteoporosis.
abstract: BACKGROUND
  Immunological arguments and historical examples have shown that treatment with cord blood for non-hematopoietic activities, such as growth factor production and stimulation of angiogenesis, may not require matching or immune suppression.
  
  
  METHODS
  To study the benefit of blood mononuclear cell therapy, 8 patients with idiopathic osteoporosis were given intermittent treatments with non-matched allogeneic cord blood mononuclear cells for 3 months. Morning fasting samples were collected for measuring urine N telopeptide of type-1 collagen, serum bone-specific alkaline phosphatase, and insulin-like growth factor 1 during one-year study.
  
  
  RESULTS
  Clinical response was striking. Serum insulin-like growth factor 1 significantly increased in all patients at 3 months compared with baseline values, from 264.1 ± 107.0 to 384.4 ± 63.1 ng/mL (P = 0.002), with a tendency to return to baseline values at 12 months (312.9 ± 75.5 ng/mL, P = 0.083). In contrast, differences in serum bone-specific alkaline phosphatase and urine N telopeptide of type-1 collagen were not significant at 3 (P = 0.765, P = 0.057) or 12 months (P = 0.889, P = 0.122). A beneficial effect on bone density was observed in all patients at the lumbar spine. The mean bone mineral density calculated during therapy (0.6811 ± 0.1442 g/cm(2)) tended higher than baseline values (0.6239 ± 0.1362 g/cm(2), P < 0), and percentage change (median) varied from 8.85% at 3 months to 7.85% at one year. All patients are now well after one year.
  
  
  CONCLUSIONS
  The findings indicate that for these patients with idiopathic osteoporosis, treatment with cord blood mononuclear cells led to a significant increase in insulin-like growth factor 1 levels, which favors the increase in bone mineral density.
authors.affiliation: Stem cell, Tissue and Organ Engineering Research Center, Kunming General, Hospital of Chinese People's Liberation Army, Kunming 650032, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Liang
authors.initials: L
authors.lastname: Zhou
authors.forename: Zheng-Ping
authors.initials: ZP
authors.lastname: Yu
authors.forename: Feng
authors.initials: F
authors.lastname: Qi
authors.forename: Bei
authors.initials: B
authors.lastname: Liu
authors.forename: Su-Xia
authors.initials: SX
authors.lastname: Zi
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: San-Bin
authors.initials: SB
authors.lastname: Wang
authors.forename: Zheng-Jiang
authors.initials: ZJ
authors.lastname: Cui
authors.forename: Xing-Hua
authors.initials: XH
authors.lastname: Pan
mesh_terms: D000328:Adult; D044466:Asian People; D015519:Bone Density / Q000502:physiology; D005006:Ethnicity; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006650:Histocompatibility Testing; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000637:transplantation*; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000628:therapy*; D014184:Transplantation, Homologous
chemical_list: D007334:Insulin-Like Growth Factor I